Gyre Therapeutics (GYRE) Competitors $10.95 +0.15 (+1.39%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GYRE vs. ACLX, CRNX, APLS, PTCT, RNA, RYTM, IMVT, ACAD, VCEL, and XENEShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Arcellx (ACLX), Crinetics Pharmaceuticals (CRNX), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), Immunovant (IMVT), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Arcellx Crinetics Pharmaceuticals Apellis Pharmaceuticals PTC Therapeutics Avidity Biosciences Rhythm Pharmaceuticals Immunovant ACADIA Pharmaceuticals Vericel Xenon Pharmaceuticals Arcellx (NASDAQ:ACLX) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings. Is ACLX or GYRE more profitable? Arcellx has a net margin of -25.94% compared to Gyre Therapeutics' net margin of -84.57%. Arcellx's return on equity of -8.28% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-25.94% -8.28% -5.21% Gyre Therapeutics -84.57%-118.43%-71.97% Which has higher earnings & valuation, ACLX or GYRE? Arcellx has higher earnings, but lower revenue than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$110.32M32.59-$70.69M-$0.71-93.63Gyre Therapeutics$113.45M9.03-$92.93MN/AN/A Does the MarketBeat Community prefer ACLX or GYRE? Arcellx received 68 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformArcellxOutperform Votes6882.93% Underperform Votes1417.07%Gyre TherapeuticsN/AN/A Does the media favor ACLX or GYRE? In the previous week, Gyre Therapeutics had 2 more articles in the media than Arcellx. MarketBeat recorded 8 mentions for Gyre Therapeutics and 6 mentions for Arcellx. Gyre Therapeutics' average media sentiment score of 0.39 beat Arcellx's score of 0.32 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, ACLX or GYRE? Arcellx has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ACLX or GYRE? 96.0% of Arcellx shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 6.2% of Arcellx shares are owned by insiders. Comparatively, 19.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer ACLX or GYRE? Arcellx presently has a consensus price target of $105.93, indicating a potential upside of 59.34%. Given Arcellx's stronger consensus rating and higher probable upside, analysts plainly believe Arcellx is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryArcellx beats Gyre Therapeutics on 11 of the 16 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$934.27M$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E RatioN/A9.4187.2917.29Price / Sales9.03310.261,255.8979.02Price / Cash40.1661.4443.8235.97Price / Book60.836.055.324.79Net Income-$92.93M$154.90M$122.78M$225.07M7 Day Performance9.61%-1.72%-0.19%1.51%1 Month Performance2.34%2.69%3.72%4.68%1 Year Performance-47.38%2.78%27.31%20.92% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.3081 of 5 stars$10.95+1.4%N/A-52.6%$934.27M$113.45M0.0040Short Interest ↑News CoverageACLXArcellx3.1719 of 5 stars$67.36-2.5%$105.93+57.3%+21.2%$3.64B$155.82M-94.87130Short Interest ↑CRNXCrinetics Pharmaceuticals3.7218 of 5 stars$38.98-4.0%$74.40+90.9%+1.5%$3.61B$1.04M-10.45210Short Interest ↑APLSApellis Pharmaceuticals4.4036 of 5 stars$28.59+4.2%$46.65+63.2%-54.6%$3.56B$715.22M-14.08770Analyst ForecastInsider TradeShort Interest ↑Gap UpPTCTPTC Therapeutics4.4928 of 5 stars$44.05+0.3%$54.08+22.8%+56.0%$3.40B$900.66M-7.421,410Analyst ForecastAnalyst RevisionNews CoverageRNAAvidity Biosciences2.0408 of 5 stars$28.41-3.6%$65.80+131.6%+169.0%$3.39B$10.12M-9.86190RYTMRhythm Pharmaceuticals4.0853 of 5 stars$54.89-2.3%$68.09+24.0%+30.7%$3.37B$112.53M-12.68140IMVTImmunovant2.171 of 5 stars$22.75-3.1%$47.22+107.6%-41.7%$3.34BN/A-10.25120Analyst ForecastInsider TradeNews CoverageACADACADIA Pharmaceuticals4.1043 of 5 stars$17.90+3.7%$25.25+41.1%-37.2%$2.98B$929.24M22.95510Short Interest ↑News CoverageVCELVericel1.7652 of 5 stars$59.62+0.2%$61.14+2.6%+56.1%$2.94B$226.84M993.83300Analyst ForecastAnalyst RevisionNews CoveragePositive NewsXENEXenon Pharmaceuticals2.7117 of 5 stars$38.25-0.4%$56.00+46.4%-15.6%$2.92B$9.43M-13.56210News CoveragePositive News Related Companies and Tools Related Companies Arcellx Competitors Crinetics Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors PTC Therapeutics Competitors Avidity Biosciences Competitors Rhythm Pharmaceuticals Competitors Immunovant Competitors ACADIA Pharmaceuticals Competitors Vericel Competitors Xenon Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GYRE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
